Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Not yet recruitingNCT07488884
ImmunityBio, Inc.Pancreatic Cancer, Pancreatic Cancer Resectable
Start: 2026-03-01End: 2029-06-01Target: 30Updated: 2026-03-23